

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.

康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT

CENTER FOR DRUG EVALUATION GRANTED PRIORITY REVIEW STATUS TO NEW DRUG APPLICATION FOR QUADRA-VALENT MENINGOCOCCAL CONJUGATE VACCINE

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Center for Drug Evaluation under the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**” and for the purpose of this announcement only, excluding Hong Kong, Macau and Taiwan) granted priority review status to the Company’s new drug application (“**NDA**”) for its groups A, C, Y and W135 meningococcal conjugate vaccine (“**MCV4**”).

The Company’s MCV4 candidate is a potential China first-in-class vaccine preventing meningitis which was found to be safe and well-tolerated, and showed good immunogenicity in age groups from 3 months to 6 years old. It is designed to be comparable to vaccines manufactured by multinational companies which are widely used in developed countries.

According to the relevant rules and regulations, the approval of the NDA for MCV4 is subject to procedures including technical review, on-site inspection of clinical trials, and on-site inspection of production.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited: We cannot guarantee that we will be able to develop, or ultimately market, MCV4 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, December 16, 2019

As at the date of this announcement, the Board of Directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive Directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive Directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive Directors.